TESTOSTERONE hormone
replacement therapy for men is
coming under increased scrutiny as
some concern has emerged around
an association between the therapy
and the potential for increased
cardiovascular (CV) risk, reports
Medscape Medical News.
The US Androgen Study Group,
who published an editorial in
the Journal of Men’s Health, has
urged the US Food and Drug
Administration (FDA) not to add a
CV boxed warning on testosterone
arguing that there are limitations in
the studies influencing its direction.
The FDA is evaluating the data.The above article was sent to subscribers in Pharmacy Daily's issue from 19 May 14 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 19 May 14
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.